On the domestic stock market on the 2nd, new drug clinical trial-related stocks showed mixed movements. While both the KOSPI and KOSDAQ fell due to weakness in U.S. semiconductor stocks and domestic large-cap semiconductor shares, clear differences in supply and demand emerged among individual bio sector stocks.

Gainers: Celltrion and Samsung Biologics Solid As of the afternoon, Celltrion was trading at 179,500 won, up 5,000 won (2.87%) from the previous trading day. Samsung Biologics also recorded 1,417,000 won, rising 21,000 won (1.50%). Additionally, SK Bioscience gained 2.45%, Hanall Biopharma 1.62%, and HK inno.N 0.72%.

Losers: HLB, ABL Bio, and Others Weaken Meanwhile, stocks with new drug development and clinical pipelines failed to avoid a downward trend. HLB traded at 48,050 won, down 2,150 won (4.28%), while HLB Pharmaceutical fell 4.43%, HLB Life Sciences 3.57%, and HLB Therapeutics 3.30%. ABL Bio declined 3.55%, Olix 5.03%, and Curient 5.81%.

Market Context and Outlook On this day, investor sentiment contracted centering on the semiconductor sector, expanding profit-taking sell-offs across growth stocks in general. The bio sector was also influenced by this atmosphere, but stock movements were differentiated based on earnings, business structures, and expectations for individual pipelines. In the market, technology transfers with global pharmaceutical companies, progress in clinical trials, and new drug approvals are cited as key variables that determine the value of bio companies. Accordingly, attention to future clinical results and R&D achievements is expected to continue.

[※ This article was written with AI assistance. This article does not constitute investment advice, and the final decision and responsibility for investments rest solely with the investor.]